Bipolar DisorderDepressive DisordersSchizophrenia

Psychedelic use and psychiatric risks

In a US-representative sample (N=2,822), lifetime naturalistic psychedelic use was associated with more lifetime unusual visual experiences and a 1.3% self-reported rate of hallucinogen persisting perception disorder, but not with greater past-two-week psychotic symptoms overall. There was an interaction with family history: psychedelic users with a family history of psychotic or bipolar disorders reported higher recent psychotic symptoms, whereas users without such a family history reported lower symptoms.

Authors

  • Otto Simonsson
  • Peter Hendricks
  • Wojciech Osika

Published

Psychopharmacology
individual Study

Abstract

Rationale

Research on psychedelics has recently shown promising results in the treatment of various psychiatric disorders, but relatively little remains known about the psychiatric risks associated with naturalistic use of psychedelics.

Objective

The objective of the current study was to investigate associations between naturalistic psychedelic use and psychiatric risks.

Methods

Using a sample representative of the US adult population with regard to sex, age, and ethnicity (N=2822), this study investigated associations between lifetime naturalistic psychedelic use, lifetime unusual visual experiences, and past 2-week psychotic symptoms.

Results

Among respondents who reported lifetime psychedelic use (n=613), 1.3% reported having been told by a doctor or other medical professional that they had hallucinogen persisting perception disorder. In covariate-adjusted linear regression models, lifetime psychedelic use was associated with more unusual visual experiences at any point across the lifetime, but no association was observed between lifetime psychedelic use and past 2-week psychotic symptoms. There was an interaction between lifetime psychedelic use and family (but not personal) history of psychotic or bipolar disorders on past 2-week psychotic symptoms such that psychotic symptoms were highest among respondents who reported lifetime psychedelic use and a family history of psychotic or bipolar disorders and lowest among those who reported lifetime psychedelic use and no family history of psychotic or bipolar disorders.

Conclusions

Although the results in this study should be interpreted with caution, the findings suggest that lifetime naturalistic use of psychedelics might be associated with more unusual visual experiences across the lifetime, as well as more psychotic symptoms in the past 2 weeks for individuals with a family history of psychotic or bipolar disorders and the reverse for those without such a family history. Future research should distinguish between different psychotic and bipolar disorders and should also utilize other research designs (e.g., longitudinal) and variables (e.g., polygenic risk scores) to better understand potential cause-and-effect relationships.

Available with Blossom Pro

Research Summary of 'Psychedelic use and psychiatric risks'

Introduction

Earlier research has shown therapeutic promise for psychedelics in treating several psychiatric disorders, but the safety evidence comes mostly from clinical trials that apply strict exclusion criteria. As a result, relatively little is known about psychiatric risks associated with naturalistic (non‑clinical) psychedelic use, particularly among groups typically excluded from trials such as people with personal or family histories of psychotic or bipolar disorders. Potential risks discussed in the literature include persistent visual phenomena (hallucinogen persisting perception disorder, HPPD) and, more rarely, onset or exacerbation of psychosis or mania, but prevalence estimates and predictors remain uncertain and prior epidemiological findings are mixed. Simonsson and colleagues set out to examine associations between lifetime naturalistic psychedelic use, unusual visual experiences, and recent psychotic symptoms in a sample intended to be representative of the US adult population by sex, age, and ethnicity. The aim was to assess whether lifetime psychedelic use relates to lifetime unusual visual phenomena and to psychotic symptoms in the past 2 weeks, and to test whether personal or family histories of psychotic or bipolar disorders modify these associations.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Pro members can view the original manuscript directly in the browser.

Study Details

References (14)

Papers cited by this study that are also in Blossom

Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies

Andersen, K. A. A., Carhart-Harris, R. L., Nutt, D. J. et al. · Acta Psychiatrica Scandinavica (2020)

Abnormal visual experiences in individuals with histories of hallucinogen use: A web-based questionnaire

Baggott, M. J., Coyle, J. R., Erowid, E. et al. · Drug and Alcohol Dependence (2011)

68 cited
Trial of Psilocybin versus Escitalopram for Depression

Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)

927 cited
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression

Goodwin, G. M., Aaronson, S. T., Alvarez, O. et al. · New England Journal of Medicine (2022)

656 cited
Hallucinogen persisting perception disorder: what do we know after 50 years?

Halpern, J. H., Pope Jr, H. G. · Drug and Alcohol Dependence (2003)

204 cited
Human hallucinogen research: guidelines for safety

Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)

Psychedelics and mental health: a population study

Krebs, T. S., Johansen, P. ˚. Ø. · PLOS ONE (2013)

Psychedelic drug use and schizotypy in young adults

Lebedev, A. V., Acar, K., Garzón, B. et al. · Scientific Reports (2021)

2 cited
Show all 14 references
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science

Neil, J. C., Nutt, D. J. · Journal of Psychopharmacology (2022)

Associations between lifetime classic psychedelic use and markers of physical health

Simonsson, O., Sexton, J. D., Hendricks, P. S. · Journal of Psychopharmacology (2021)

65 cited
Adverse Reactions to Psychedelic Drugs - A Review of the Literature

Strassman, R. J. · Journal of Nervous and Mental Disease (1984)

273 cited

Cited By (3)

Papers in Blossom that reference this study

Do Psychedelics Mimic Psychosis? Perspectives on Similarities and Differences from Individuals with Lived Experience of Psychosis and Psychedelics

Dourron, H. M., Bradley, M. K., Copes, H. et al. · International Journal of Mental Health and Addiction (2026)

Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial

Bradley, E. R., Sakai, K., Fernandes-Osterhold, G. et al. · Neuropsychopharmacology (2025)

10 cited

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.